Prenetics Global ($NASDAQ:PRE) recently reported its financial results for the period, reporting a revenue of $4.86M and a GAAP EPS of -$0.08. This comes as a disappointment to investors as the company had previously forecasted a much higher revenue and EPS. PRENETICS GLOBAL is a biotechnology company focused on delivering data-driven solutions to healthcare systems around the globe. The company’s products range from genetic testing kits to AI-assisted diagnostic systems and its services span from personalized healthcare to access to personalized health insurance. The company seeks to be a leader in the field of precision medicine and healthcare technology.
As a result of its innovative approach to healthcare, PRENETICS GLOBAL has been able to secure strategic partnerships with major healthcare providers around the world. The financial results reported by Prenetics Global are certainly concerning, as investors had expected the company to outperform its previous expectations. In the face of this, Prenetics Global will need to continue to innovate in order to stay competitive in the healthcare sector. With a focus on providing personalized healthcare solutions and access to cutting-edge technology, Prenetics Global is well-positioned to continue to be a leader in the field of precision medicine and healthcare technology.
In the latest earning report of Fiscal Year 2023 Q2 ending June 30 2021, PRENETICS GLOBAL reported total revenue of 79.02M USD and a net loss of 9.77M USD, resulting in a GAAP EPS of -$0.08. This marks a 52.8% increase in total revenue compared to the same period last year.
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Prenetics Global. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Prenetics Global. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Prenetics Global. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Prenetics Global are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
The news resulted in an increase of 1.5% in the stock price, with the opening price being 4.6 and the closing price being 4.7. This is compared to the previous closing price of 4.6. The PRENETICS GLOBAL stock performed well amid challenging market conditions. In spite of this, PRENETICS GLOBAL continues to deliver solid financial results and remains committed to creating value for its shareholders. Live Quote…
Analysis – Prenetics Global Intrinsic Value
GoodWhale has conducted an analysis of PRENETICS GLOBAL‘s wellbeing, and our proprietary Valuation Line has calculated the fair value of PRENETICS GLOBAL’s share to be around $44.7. However, at the time of writing, PRENETICS GLOBAL’s stock is being traded at $4.7, indicating that it is undervalued by 89.5%. More…
Star Chart Analysis
Prenetics Global Ltd is in a highly competitive industry with several large players in the market. The main competitors of Prenetics Global Ltd are Genetic Technologies Ltd, Shanghai Labway Clinical Laboratory Co Ltd, RushNet Inc, and other companies. All these companies are striving to provide the best services in the field of healthcare and genetic testing, and the competition is resulting in improved products and services for customers.
– Genetic Technologies Ltd ($ASX:GTG)
Genetic Technologies Ltd is an Australian-based biotechnology company that specializes in genetic testing and predictive assessment services. The company has a market capitalization of 34.62M as of 2023 which implies that the company is of medium size and is a well established in the market. Additionally, its Return on Equity (ROE) of -40.35% suggests that the company is not generating enough profit to cover the shareholders’ investments. Despite this, the company has been able to successfully implement its products and services in order to provide reliable results for those who are interested in such a service.
– Shanghai Labway Clinical Laboratory Co Ltd ($SZSE:301060)
Shanghai Labway Clinical Laboratory Co Ltd is a leading provider of medical testing services in China. It specializes in clinical laboratory services, genetic testing, and clinical diagnostics. As of 2023, the company has a market cap of 7.59 billion and a Return on Equity of 29.66%. This demonstrates the company’s efficiency in generating profits from its investments. The company has also been able to increase its market share and extend its reach to large companies and institutions, allowing it to further increase its profits.
Prenetics Global has reported a Global GAAP Earnings Per Share (EPS) of -$0.08 and revenue of $4.86M for its most recent period. Investors looking to assess the company’s stock should take into account this data when making their decisions. While the negative EPS is concerning, it is important to consider the potential for growth and the company’s ability to generate returns on their investments.
Additionally, investors should consider the company’s financials, including cash flow and debt levels, to better understand the company’s financial health. Furthermore, it is important to analyze the company’s market position and competitive landscape to determine if new opportunities or risks exist. Finally, considering the company’s management team, strategy, and future prospects can also help investors form an opinion on the stock. Ultimately, Prenetics Global’s financials and outlook should be carefully analyzed in order to make a fully informed decision on whether to invest in the company.